Yan Ren

Structure of the human Cereblon–DDB1–lenalidomide complex reveals basis for responsiveness to thalidomide analogs

Philip P. Chamberlain, Antonia Lopez‐Girona, Karen Miller et al. · Nature Structural & Molecular Biology · 2014 · 515 citations

Medicine, Medicinal Chemistry, Pharmacology +5

SALL4 mediates teratogenicity as a thalidomide-dependent cereblon substrate

Mary E. Matyskiela, Suzana S. Couto, Xinde Zheng et al. · Nature Chemical Biology · 2018 · 343 citations

Life Sciences, Molecular Biology, Pharmacology +5

Rate of CRL4CRBN substrate Ikaros and Aiolos degradation underlies differential activity of lenalidomide and pomalidomide in multiple myeloma cells by regulation of c-Myc and IRF4

Chad C. Bjorklund, Ling Lu, Jian Kang et al. · Blood Cancer Journal · 2015 · 217 citations · Full text

Life Sciences, Molecular Biology, Pharmacology +17

Iberdomide (CC-220) is a potent cereblon E3 ligase modulator with antitumor and immunostimulatory activities in lenalidomide- and pomalidomide-resistant multiple myeloma cells with dysregulated CRBN

Chad C. Bjorklund, Jian Kang, Michael Amatangelo et al. · Leukemia · 2019 · 196 citations · Full text

Medicine, Oncology, Pharmacology +15

Clinical and pharmacodynamic analysis of pomalidomide dosing strategies in myeloma: impact of immune activation and cereblon targets

Kartik Sehgal, Rituparna Das, Lin Zhang et al. · Blood · 2015 · 132 citations · Full text

Medicine, Hematology, Pharmacology +16